H. R. 6—165 
with a substance use disorder, including programs that 
mentor and provide support services to children; 
‘‘(iii) the resources available to help support 
individuals in recovery; and 
‘‘(iv) related medical outcomes of substance use 
disorders, the potential of acquiring an infection com-
monly associated with illicit drug use, and neonatal 
abstinence syndrome among infants exposed to opioids 
during pregnancy. 
‘‘(e) SPECIAL CONSIDERATION.—In carrying out this section, the 
Secretary shall give special consideration to the unique needs of 
rural areas, including areas with an age-adjusted rate of drug 
overdose deaths that is above the national average and areas with 
a shortage of prevention and treatment services. 
‘‘(f) AUTHORIZATION OF APPROPRIATIONS.—There is authorized 
to be appropriated to carry out this section $5,000,000 for each 
of fiscal years 2019 through 2023.’’. 
SEC. 7152. PEER SUPPORT TECHNICAL ASSISTANCE CENTER. 
Title V of the Public Health Service Act (42 U.S.C. 290dd 
et seq.) is amended by inserting after section 547 the following: 
‘‘SEC. 547A. PEER SUPPORT TECHNICAL ASSISTANCE CENTER. 
‘‘(a) ESTABLISHMENT.—The Secretary, acting through the Assist-
ant Secretary, shall establish or operate a National Peer-Run 
Training and Technical Assistance Center for Addiction Recovery 
Support (referred to in this section as the ‘Center’). 
‘‘(b) FUNCTIONS.—The Center established under subsection (a) 
shall provide technical assistance and support to recovery commu-
nity organizations and peer support networks, including such assist-
ance and support related to— 
‘‘(1) training on identifying— 
‘‘(A) signs of substance use disorder; 
‘‘(B) resources to assist individuals with a substance 
use disorder, or resources for families of an individual 
with a substance use disorder; and 
‘‘(C) best practices for the delivery of recovery support 
services; 
‘‘(2) the provision of translation services, interpretation, 
or other such services for clients with limited English speaking 
proficiency; 
‘‘(3) data collection to support research, including for 
translational research; 
‘‘(4) capacity building; and 
‘‘(5) evaluation and improvement, as necessary, of the 
effectiveness of such services provided by recovery community 
organizations. 
‘‘(c) BEST PRACTICES.—The Center established under subsection 
(a) shall periodically issue best practices for use by recovery commu-
nity organizations and peer support networks. 
‘‘(d) RECOVERY COMMUNITY ORGANIZATION.—In this section, the 
term ‘recovery community organization’ has the meaning given 
such term in section 547. 
‘‘(e) AUTHORIZATION OF APPROPRIATIONS.—There is authorized 
to be appropriated to carry out this section $1,000,000 for each 
of fiscal years 2019 through 2023.’’.
H. R. 6—166 
Subtitle Q—Creating Opportunities That 
Necessitate New and Enhanced Connec-
tions That Improve Opioid Navigation 
Strategies 
SEC. 7161. PREVENTING OVERDOSES OF CONTROLLED SUBSTANCES. 
(a) IN GENERAL.—Part J of title III of the Public Health Service 
Act (42 U.S.C. 280b et seq.) is amended by inserting after section 
392 (42 U.S.C. 280b–1) the following: 
‘‘SEC. 392A. PREVENTING OVERDOSES OF CONTROLLED SUBSTANCES. 
‘‘(a) EVIDENCE-BASED PREVENTION GRANTS.— 
‘‘(1) IN GENERAL.—The Director of the Centers for Disease 
Control and Prevention may— 
‘‘(A) to the extent practicable, carry out and expand 
any evidence-based prevention activities described in para-
graph (2); 
‘‘(B) provide training and technical assistance to States, 
localities, and Indian tribes for purposes of carrying out 
such activity; and 
‘‘(C) award grants to States, localities, and Indian 
tribes for purposes of carrying out such activity. 
‘‘(2) EVIDENCE-BASED
PREVENTION
ACTIVITIES.—An evi-
dence-based prevention activity described in this paragraph 
is any of the following activities: 
‘‘(A) Improving the efficiency and use of a new or 
currently operating prescription drug monitoring program, 
including by— 
‘‘(i) encouraging all authorized users (as specified 
by the State or other entity) to register with and use 
the program; 
‘‘(ii) enabling such users to access any updates 
to information collected by the program in as close 
to real-time as possible; 
‘‘(iii) improving the ease of use of such program; 
‘‘(iv) providing for a mechanism for the program 
to notify authorized users of any potential misuse or 
abuse of controlled substances and any detection of 
inappropriate prescribing or dispensing practices 
relating to such substances; 
‘‘(v) encouraging the analysis of prescription drug 
monitoring data for purposes of providing de-identified, 
aggregate reports based on such analysis to State 
public health agencies, State substance abuse agencies, 
State licensing boards, and other appropriate State 
agencies, as permitted under applicable Federal and 
State law and the policies of the prescription drug 
monitoring program and not containing any protected 
health information, to prevent inappropriate pre-
scribing, drug diversion, or abuse and misuse of con-
trolled substances, and to facilitate better coordination 
among agencies; 
‘‘(vi) enhancing interoperability between the pro-
gram and any health information technology (including
H. R. 6—167 
certified health information technology), including by 
integrating program data into such technology; 
‘‘(vii) updating program capabilities to respond to 
technological innovation for purposes of appropriately 
addressing the occurrence and evolution of controlled 
substance overdoses; 
‘‘(viii) facilitating and encouraging data exchange 
between the program and the prescription drug moni-
toring programs of other States; 
‘‘(ix) enhancing data collection and quality, 
including improving patient matching and proactively 
monitoring data quality; 
‘‘(x) providing prescriber and dispenser practice 
tools, including prescriber practice insight reports for 
practitioners to review their prescribing patterns in 
comparison to such patterns of other practitioners in 
the specialty; and 
‘‘(xi) meeting the purpose of the program estab-
lished under section 399O, as described in section 
399O(a). 
‘‘(B) Promoting community or health system interven-
tions. 
‘‘(C) Evaluating interventions to prevent controlled sub-
stance overdoses. 
‘‘(D) Implementing projects to advance an innovative 
prevention approach with respect to new and emerging 
public health crises and opportunities to address such 
crises, such as enhancing public education and awareness 
on the risks associated with opioids. 
‘‘(3) ADDITIONAL GRANTS.—The Director may award grants 
to States, localities, and Indian Tribes— 
‘‘(A) to carry out innovative projects for grantees to 
rapidly respond to controlled substance misuse, abuse, and 
overdoses, including changes in patterns of controlled sub-
stance use; and 
‘‘(B) for any other evidence-based activity for pre-
venting controlled substance misuse, abuse, and overdoses 
as the Director determines appropriate. 
‘‘(4) RESEARCH.—The Director, in coordination with the 
Assistant Secretary for Mental Health and Substance Use and 
the National Mental Health and Substance Use Policy Labora-
tory established under section 501A, as appropriate and 
applicable, may conduct studies and evaluations to address 
substance use disorders, including preventing substance use 
disorders or other related topics the Director determines appro-
priate. 
‘‘(b) ENHANCED
CONTROLLED
SUBSTANCE
OVERDOSE
DATA 
COLLECTION, ANALYSIS, AND DISSEMINATION GRANTS.— 
‘‘(1) IN GENERAL.—The Director of the Centers for Disease 
Control and Prevention may— 
‘‘(A) to the extent practicable, carry out any controlled 
substance overdose data collection activities described in 
paragraph (2); 
‘‘(B) provide training and technical assistance to States, 
localities, and Indian tribes for purposes of carrying out 
such activity;
H. R. 6—168 
‘‘(C) award grants to States, localities, and Indian 
tribes for purposes of carrying out such activity; and 
‘‘(D) coordinate with the Assistant Secretary for Mental 
Health and Substance Use to collect data pursuant to sec-
tion 505(d)(1)(A) (relating to the number of individuals 
admitted to emergency departments as a result of the 
abuse of alcohol or other drugs). 
‘‘(2) CONTROLLED SUBSTANCE OVERDOSE DATA COLLECTION 
AND
ANALYSIS
ACTIVITIES.—A controlled substance overdose 
data collection, analysis, and dissemination activity described 
in this paragraph is any of the following activities: 
‘‘(A) Improving the timeliness of reporting data to the 
public, including data on fatal and nonfatal overdoses of 
controlled substances. 
‘‘(B) Enhancing the comprehensiveness of controlled 
substance overdose data by collecting information on such 
overdoses from appropriate sources such as toxicology 
reports, autopsy reports, death scene investigations, and 
emergency departments. 
‘‘(C) Modernizing the system for coding causes of death 
related to controlled substance overdoses to use an elec-
tronic-based system. 
‘‘(D) Using data to help identify risk factors associated 
with controlled substance overdoses. 
‘‘(E) Supporting entities involved in providing informa-
tion on controlled substance overdoses, such as coroners, 
medical examiners, and public health laboratories to 
improve accurate testing and standardized reporting of 
causes and contributing factors to controlled substances 
overdoses and analysis of various opioid analogues to con-
trolled substance overdoses. 
‘‘(F) Working to enable and encourage the access, 
exchange, and use of information regarding controlled sub-
stance overdoses among data sources and entities. 
‘‘(c) DEFINITIONS.—In this section: 
‘‘(1) CONTROLLED SUBSTANCE.—The term ‘controlled sub-
stance’ has the meaning given that term in section 102 of 
the Controlled Substances Act. 
‘‘(2) INDIAN TRIBE.—The term ‘Indian tribe’ has the meaning 
given that term in section 4 of the Indian Self-Determination 
and Education Assistance Act. 
‘‘(d) AUTHORIZATION OF APPROPRIATIONS.—For purposes of car-
rying out this section, section 399O of this Act, and section 102 
of the Comprehensive Addiction and Recovery Act of 2016 (Public 
Law 114–198), there is authorized to be appropriated $496,000,000 
for each of fiscal years 2019 through 2023.’’. 
(b) EDUCATION
AND AWARENESS.—Section 102 of the Com-
prehensive Addiction and Recovery Act of 2016 (Public Law 114– 
198) is amended— 
(1) by amending subsection (a) to read as follows: 
‘‘(a) IN GENERAL.—The Secretary of Health and Human Serv-
ices, acting through the Director of the Centers for Disease Control 
and Prevention and in coordination with the heads of other depart-
ments and agencies, shall advance education and awareness 
regarding the risks related to misuse and abuse of opioids, as 
appropriate, which may include developing or improving existing